You can find the news in detail here.
Two trials of COX-2 inhibitors conducted in 2004 at other institutions suggested that risk of cardiovascular disease might increase gradually during continued treatment with drugs such as Celebrex and Vioxx, even in individuals initially at low risk of the disease.
Additional information appeared online in the January 17, 2005 issue of Circulation and in the January 25th print edition of the journal. You can find it online here.
